PuriCore plc is the developer of a novel, safe technology that mimics the human body's natural anti-microbial, hypochlorous acid. Last week, the company announced that it has received 510(k) clearance from the USFDA to market its proprietary VASHE™ Wound Cleansing System as a medical device.

The VASHE™ System produces a highly effective solution which is indicated for use in wound cleansing, irrigating, moistening and debriding acute and chronic dermal lesions.

It will target indications such as Stage I-IV pressure ulcers, stasis ulcers, diabetic ulcers, post surgical wounds, first and second degree burns, abrasions and minor irritations of the skin.

The VASHE™ System, based on existing patented and patent pending PuriCore technology and products that produce hypochlorous acid from the electrolysis of a saline solution from a table top or floor mounted system, is the first wound cleansing system of its kind that can produce a solution on-site at the point of use by the clinician.

Read more at PuriCore plc.